First AD

Second AD

Alan Tan, MD, is an associate professor of medicine in the Division of Hematology Oncology at Vanderbilt University Medical Center and a genitourinary oncology and melanoma specialist at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

Laurence Albiges, MD, PhD, is head of the Department of Oncology at Institut Gustave Roussy

critical factors influencing decisions for frontline therapy in metastatic renal cell carcinoma 

Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC 

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma

Peer Exchange

Huntsman Cancer Institute at the University of Utah 

Cancer Centers

Partner

The University of Texas MD Anderson Cancer Center

Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.